Directorio

The Alzheimer's Disease Discoveries in Medicine (ADD ME) project is a list of adults who want to help with research at the Duke/UNC Alzheimer's Disease Research Center. This list helps connect people who are ready to join studies with researchers who are learning what causes Alzheimer's disease and how to keep the brain healthy.

We are doing this study to look at components of the blood to see if there are features that distinguish people with dystonia from people without dystonia. Identifying "biomarkers" in the blood that are associated with dystonia is greatly needed to help more accurately diagnosis dystonia and to identify subsets of dystonias that may have shared mechanisms. Being able to group individuals by underlying mechanisms can guide people with dystonia to the most appropriate future treatments that act specifically to correct one cause or another.

We are doing this study to find out if infusing chemotherapy drugs directly into the hepatic artery (the blood vessel that supplies blood to the liver) is a better treatment option than standard chemotherapy for people who have colorectal cancer that has spread to the liver.

We are doing this study to compare the results of typical chemotherapy on its own to high dose chemotherapy followed by stem cell infusion after completing the usual chemotherapy. We want to know which option has the best outcomes for people with periperhal T-cell lymphoma.

If people join this study, they will be placed into one of two groups by chance. One group will have the usual surgery to remove the melanoma along with a procedure to check nearby lymph nodes. The other group will have only the surgery to remove the melanoma. After surgery, doctors will watch for any signs that the melanoma has come back. Participants will complete surveys about their health and quality of life every four months for the first two years. After that, they will continue seeing their doctors every six months for three more years. If the melanoma returns after the first two years, participants will be asked to complete another survey at that time.

We are doing this study to compare the usual treatments of surgery alone to using chemotherapy before surgery. We want to know if adding doxorubicin and ifosfamide chemotherapy for liposarcoma (LPS) or doxorubicin and dacarbazine chemotherapy for leiomyosarcoma (LMS) before surgery can improve the long-term survival for patients with these cancers.

We are doing this study to identify patients who have gene changes or mutations in their tumor(s) and might be eligible for treatment using a combination of targeted therapy options. This study is called ComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice).